Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Hum Reprod Update. 2010 Nov-Dec;16(6):651-74. doi: 10.1093/humupd/dmq009. Epub 2010 May 12.
Endometriosis is estimated to affect 1 in 10 women during the reproductive years. There is often delay in making the diagnosis, mainly due to the non-specific nature of the associated symptoms and the need to verify the disease surgically. A biomarker that is simple to measure could help clinicians to diagnose (or at least exclude) endometriosis; it might also allow the effects of treatment to be monitored. If effective, such a marker or panel of markers could prevent unnecessary diagnostic procedures and/or recognize treatment failure at an early stage.
We used QUADAS (Quality Assessment of Diagnostic Accuracy Studies) criteria to perform a systematic review of the literature over the last 25 years to assess critically the clinical value of all proposed biomarkers for endometriosis in serum, plasma and urine.
We identified over 100 putative biomarkers in publications that met the selection criteria. We were unable to identify a single biomarker or panel of biomarkers that have unequivocally been shown to be clinically useful.
Peripheral biomarkers show promise as diagnostic aids, but further research is necessary before they can be recommended in routine clinical care. Panels of markers may allow increased sensitivity and specificity of any diagnostic test.
子宫内膜异位症估计在生育期影响每 10 名女性中的 1 名。由于相关症状的非特异性和需要手术验证疾病,因此常常会延迟做出诊断。一种简单的测量生物标志物可以帮助临床医生诊断(或至少排除)子宫内膜异位症;它还可以监测治疗效果。如果有效,这种标志物或标志物组合可以防止不必要的诊断程序,并/或在早期识别治疗失败。
我们使用 QUADAS(诊断准确性研究的质量评估)标准对过去 25 年的文献进行了系统回顾,以批判性地评估所有在血清、血浆和尿液中提出的用于子宫内膜异位症的候选生物标志物的临床价值。
我们在符合选择标准的出版物中发现了 100 多种潜在的生物标志物。我们无法确定任何一种或一组生物标志物已经明确具有临床用途。
外周生物标志物作为诊断辅助工具显示出前景,但在推荐用于常规临床护理之前,还需要进一步研究。标志物组合可能会提高任何诊断测试的灵敏度和特异性。